Endacea, Inc., an emerging biopharmaceutical company, is developing a series of proprietary A1 adenosine receptor (AR) antagonists as drug candidates for a number of medical indications, including: 1) inflammation, including sepsis and asthma; and 2) renal impairment. Endacea is advancing the company’s lead compound A1 AR antagonist, L-97-1, as an i.v. anti-sepsis drug candidate and as a post-exposure medical countermeasure for plague and other biodefense indications. Endacea is also developing a sensitive and specific biomarker for sepsis as a companion diagnostic for Endacea’s i.v. anti-sepsis drug candidate and for other uses.